# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Naz Rahman reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $22.5 price target.
TGTX: 31% | TG Therapeutics shares are trading higher following a Q1 revenue beat and increased 2024 Briumvi US net product rev...
TGTX: 31% | TG Therapeutics shares are trading higher following a Q1 revenue beat and increased 2024 Briumvi US net product rev...